Exosomes News and Research

RSS

Viruses lead to discovery of security system in host cells

Viruses have led scientists at Washington University School of Medicine in St. Louis to the discovery of a security system in host cells.

18 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

New findings shed light on biology of neuropsychiatric diseases

The biggest surprise to me was that we could rescue the autistic phenotype [in the human cells] to something close to normal, said Alysson Muotri of the University of California San Diego.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Scientists create functional neurons to study ASD development

Using induced pluripotent stem cells from patients with Rett syndrome, scientists at the University of California, San Diego School of Medicine have created functional neurons that provide the first human cellular model for studying the development of autism spectrum disorder (ASD) and could be used as a tool for drug screening, diagnosis and personalized treatment.

12 Nov 2010

Research reveals EBV virus infected cell manipulates cancer-producing cells

A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.

9 Nov 2010

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

One of the most frustrating problems faced by doctors who treat pancreatic cancer is the lack of effective therapeutic options. More than 38,000 people in the United States die of the disease each year, and new drugs and treatments are desperately needed.

8 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

Essential Pharmaceuticals to commence sales of cell media products acquired from Lifeblood Medical

Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell® name.

28 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

RWV bioreactor creates 3-D cell culture models

The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.

20 Oct 2010

Vitro signs contract with HemoGenix to manufacture, distribute stem cell analysis tools

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.

20 Oct 2010

Researchers explain nano-topographical responsiveness of stem cells

Many scientists aspire to take control over the stem cell differentiation process, so that we can grow organs and implants perfectly matched to each patient in the future. Now research in the Journal of Tissue Engineering, published by SAGE-Hindawi, explains how engineering the topography on which stem cells grow, and the mechanical forces working on them, can be as powerful an agent for change as their chemical environment.

8 Oct 2010

Laureate Pharma secures $20 million financing to enhance business

Laureate Pharma, Inc., a full-service contract development and manufacturing organization today announced that it has secured $20 million in debt and equity financing to enhance and grow its business.

7 Oct 2010

New approach method could simplify study and treatment of human diseases

Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them.

6 Oct 2010

Corning acquires Plaslab

Corning Incorporated announced today that it has completed the previously announced acquisition of all outstanding shares of Plaslab S.A.S. from certain investment funds managed by Qualium Investissement and from the other shareholders of Plaslab. Plaslab is the holding company of Plastiques Gosselin.

4 Oct 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010